Longitude Capital Partners III, LLC 3
3 · Inozyme Pharma, Inc. · Filed Jul 23, 2020
Insider Transaction Report
Form 3
Longitude Capital Partners III, LLC
10% Owner
Holdings
- (indirect: By Longitude Venture Partners III, L.P.)
Series A Convertible Preferred Stock
→ Common Stock (2,007,225 underlying) - (indirect: By Longitude Venture Partners III, L.P.)
Series A-2 Convertible Preferred Stock
→ Common Stock (187,154 underlying)
Footnotes (3)
- [F1]The Series A Convertible Preferred Stock is convertible into Common Stock on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- [F2]These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]The Series A-2 Convertible Preferred Stock is convertible into Common Stock on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.